Ovarian Cancer: Frontline Therapy

Video

Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Related Content
The FDA has assigned a Prescription Drug User Fee Act date of July 11, 2026, for relacorilant as a treatment for platinum-resistant ovarian cancer.

FDA Accepts Relacorilant NDA for Platinum-Resistant Ovarian Cancer

Roman Fabbricatore
September 12th 2025
Article
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
September 12th 2025
Podcast
Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer

Ariana Pelosci
September 12th 2025
Article
Target Folate Receptor Alpha in Ovarian Cancer?

Target Folate Receptor Alpha in Ovarian Cancer?

Dmitriy Zamarin, MD, PhD
September 12th 2025
Podcast
Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission

Russ Conroy
September 12th 2025
Article
Oncologists explore the considerations of mirvetuximab soravtansine treatment in platinum-resistant ovarian cancer, highlighting its efficacy and the management of ocular AEs.

Highlighting Multidisciplinary Ovarian Cancer Care With Oncologists, Ophthalmologists, and Nurses

ONCOLOGY Staff
September 12th 2025
Article